Next-gen assets including bispecific zanidatamab, HER2-targeted TUKYSA (tucatinib), and new monoclonal antibodies like zolbetuximab are undergoing advanced clinical development. https://www.einpresswire.com/article/833965726/her2-gastric-cancer-therapy-market-set-for-steady-growth-by-2033-datam-intelligence